David Nierengarten
Stock Analyst at Wedbush
(4.13)
# 529
Out of 5,044 analysts
206
Total ratings
51.79%
Success rate
12.97%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.50 | +366.67% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $88.85 | +23.80% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $36.47 | +91.94% | 14 | Oct 15, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $800 → $880 | $825.43 | +6.61% | 22 | Oct 13, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $40.43 | +8.83% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $5.07 | +18.34% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $99.68 | +15.37% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $1.98 | +102.02% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $14.20 | +83.10% | 8 | Sep 2, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.72 | +105.32% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $11.31 | +121.04% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.99 | +16.86% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $27.74 | -71.16% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.01 | +265.45% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $13.99 | -28.52% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $13.57 | +98.97% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $16.48 | +100.24% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.11 | +80.18% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $17.01 | +82.25% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $56.40 | +59.57% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $29.20 | +60.96% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $13.38 | +49.53% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $27.47 | +45.61% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $24.72 | +82.04% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.19 | +356.62% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $4.93 | +265.48% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $15.89 | -37.07% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.93 | +143.41% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $26.06 | +118.77% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $10.40 | +1,582.69% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.48 | +14,267.82% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.43 | +833.13% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.71 | +118.14% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $34.54 | +117.14% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.80 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.18 | - | 3 | Nov 20, 2017 |
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.50
Upside: +366.67%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $88.85
Upside: +23.80%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $36.47
Upside: +91.94%
argenx SE
Oct 13, 2025
Maintains: Outperform
Price Target: $800 → $880
Current: $825.43
Upside: +6.61%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $40.43
Upside: +8.83%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $5.07
Upside: +18.34%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $99.68
Upside: +15.37%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $1.98
Upside: +102.02%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $14.20
Upside: +83.10%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $10.72
Upside: +105.32%
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $11.31
Upside: +121.04%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.99
Upside: +16.86%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $27.74
Upside: -71.16%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.01
Upside: +265.45%
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $13.99
Upside: -28.52%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $13.57
Upside: +98.97%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $16.48
Upside: +100.24%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.11
Upside: +80.18%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $17.01
Upside: +82.25%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $56.40
Upside: +59.57%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $29.20
Upside: +60.96%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $13.38
Upside: +49.53%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $27.47
Upside: +45.61%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $24.72
Upside: +82.04%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.19
Upside: +356.62%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $4.93
Upside: +265.48%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $15.89
Upside: -37.07%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.93
Upside: +143.41%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $26.06
Upside: +118.77%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $10.40
Upside: +1,582.69%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.48
Upside: +14,267.82%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.43
Upside: +833.13%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.71
Upside: +118.14%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $34.54
Upside: +117.14%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.80
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.18
Upside: -